Review
Pharmacology & Pharmacy
Dulce C. Macias-Ceja, Maria D. Barrachina, Dolores Ortiz-Masia
Summary: Chronic inflammation is associated with excessive deposition of extracellular matrix and leads to fibrosis. Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD), and deregulated autophagy is linked to fibrosis progression. Understanding the role of autophagy in fibrosis may provide new targets for antifibrotic therapy. This review focuses on the relevance of autophagy in fibrosis, with a special emphasis on IBD-related fibrosis.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Immunology
Yifei Wang, Bin Huang, Tao Jin, Dickson Kofi Wiredu Ocansey, Jiajia Jiang, Fei Mao
Summary: Intestinal fibrosis, as a complication of inflammatory bowel disease, is mainly induced by chronic inflammation. Current anti-inflammatory drugs are ineffective in preventing and alleviating fibrosis, making surgery the main treatment option. Mesenchymal stem cells (MSCs) have the potential for tissue regeneration and repair, but their specific role in intestinal fibrosis needs further investigation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Stefano Levra, Giuseppe Guida, Andrea Elio Sprio, Flavio Crosa, Paolo Carlo Ghio, Francesca Bertolini, Vitina Carriero, Carlo Albera, Fabio Luigi Massimo Ricciardolo
Summary: This study explores the safety profile of pirfenidone and nintedanib in the treatment of IPF and finds that adverse events caused by nintedanib are generally easier to manage and result in fewer cases of permanent drug discontinuation.
Article
Gastroenterology & Hepatology
Giorgos Bamias, Theresa T. Pizarro, Fabio Cominelli
Summary: This review describes the cellular and molecular immunological mechanisms of intestinal fibrosis in IBD, with a particular focus on animal models of intestinal fibrosis. Based on this research, potential future targets for antifibrotic therapies for IBD patients can be identified.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Multidisciplinary Sciences
Qichen Shen, Zhuizui Huang, Jiachen Yao, Yuanxiang Jin
Summary: This review discusses the modulatory functions of extracellular vesicles (EVs) in the intestine, with a focus on their roles and applications in the clinical therapy of inflammatory bowel disease (IBD). By establishing EV-mediated interaction systems between host intestine and microbiota, the possible mechanisms of IBD pathogenesis and its cure are described.
JOURNAL OF ADVANCED RESEARCH
(2022)
Review
Medicine, General & Internal
John N. Shumar, Abhimanyu Chandel, Christopher S. King
Summary: Progressive fibrosing interstitial lung disease (PF-ILD) is a subset of interstitial lung diseases characterized by progressive and intractable lung fibrosis, with similarities to idiopathic pulmonary fibrosis. Recent studies have shown the clinical efficacy of antifibrotic therapy in PF-ILD, changing the treatment landscape for fibrotic lung diseases and opening the door for combined therapies targeting both fibrotic and inflammatory components.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Urology & Nephrology
Marta Ruiz-Ortega, Santiago Lamas, Alberto Ortiz
Summary: Kidney fibrosis is a characteristic of chronic kidney disease and a potential target for therapy. However, there are challenges in directly targeting kidney fibrosis. It is unclear whether fibrosis causes or results from CKD progression, and there is a lack of tools to assess kidney fibrosis in clinical practice.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2022)
Review
Cell Biology
Dulce C. Macias-Ceja, M. Teresa Mendoza-Ballesteros, Maria Ortega-Albiach, M. Dolores Barrachina, Dolores Ortiz-Masia
Summary: Chronic inflammation in inflammatory bowel disease (IBD) can lead to tissue damage and remodeling, ultimately resulting in fibrosis. Epithelial cells play a key role in fibrosis by promoting fibroblast activation and extracellular matrix deposition. Additionally, epithelial cells can undergo epithelial-mesenchymal transition and directly contribute to fibroblast activation and extracellular matrix deposition. Understanding these complex interactions may provide new therapeutic targets for preventing or treating fibrosis in IBD.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Respiratory System
Timothy M. Dempsey, Stephanie Payne, Lindsey Sangaralingham, Xiaoxi Yao, Nilay D. Shah, Andrew H. Limper
Summary: Since their approval in 2014, the adoption of pirfenidone and nintedanib in the United States has been low, which may be associated with the high out-of-pocket costs.
ANNALS OF THE AMERICAN THORACIC SOCIETY
(2021)
Article
Respiratory System
Kevin G. Dsouza, Ranu Surolia, Tejaswini Kulkarni, Fu Jun Li, Pooja Singh, Huaxiu Zeng, Crystal Stephens, Abhishek Kumar, Zheng Wang, Veena B. Antony
Summary: A patient derived 3D organoid model was developed to mimic the disease process of ILDs and test the response to antifibrotic drugs. The model shows individual variations in invasiveness and could be used for personalized medicine and drug development in ILDs and other chronic lung diseases.
RESPIRATORY RESEARCH
(2023)
Review
Critical Care Medicine
Tananchai Petnak, Ploypin Lertjitbanjong, Charat Thongprayoon, Teng Moua
Summary: Meta-analysis of 26 studies showed that antifibrotic treatment reduced the risk of all-cause mortality and acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF).
Article
Gastroenterology & Hepatology
Bin Liu, Mu-Qing Yang, Tian-Yu Yu, Yang-Yang Yin, Ying Liu, Xiao-Dong Wang, Zhi-Gang He, Lu Yin, Chun-Qiu Chen, Ji-Yu Li
Summary: In this study, it was found that mast cell tryptase promotes inflammatory bowel disease-induced intestinal fibrosis by activating the PAR-2/Akt/mTOR pathway of fibroblasts. Tryptase stored in mast cell granules is released into fibrotic intestinal tissues, leading to increased expression of tryptase and differentiation of fibroblasts into fibrotic-phenotype myofibroblasts. Inhibition of tryptase reduced intestinal fibrosis, indicating the potential for targeting tryptase as a therapeutic strategy for intestinal fibrosis.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Cardiac & Cardiovascular Systems
Takuma Isshiki, Susumu Sakamoto, Akira Yamasaki, Hiroshige Shimizu, Shion Miyoshi, Yasuhiko Nakamura, Sakae Homma, Kazuma Kishi
Summary: The study found that the incidence of AE-IPF was lower in IPF patients receiving antifibrotic agents, with a lower incidence in the pirfenidone group compared to the nintedanib group. The survival rates after AE-IPF onset were similar between the two groups.
RESPIRATORY MEDICINE
(2021)
Review
Immunology
Inge Jacobs, Matthias Ceulemans, Lucas Wauters, Christine Breynaert, Severine Vermeire, Bram Verstockt, Tim Vanuytsel
Summary: Eosinophils, a type of white blood cell, play a crucial role in gastrointestinal health and are increasingly being studied for their inflammatory and pro-fibrotic functions in inflammatory bowel disease and other chronic inflammatory conditions. Research focus is shifting towards innate immunity and understanding the inflammatory properties of eosinophils.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Rolf Reiter, Florian N. Loch, Carsten Kamphues, Christian Bayerl, Stephan R. Marticorena Garcia, Britta Siegmund, Anja A. Kuehl, Bernd Hamm, Juergen Braun, Ingolf Sack, Patrick Asbach
Summary: This study tested the feasibility of MR elastography of the gut in healthy volunteers and IBD patients, showing excellent diagnostic performance in predicting IBD.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2022)
Article
Medicine, General & Internal
Guanwei Li, Jianan Ren, Gefei Wang, Qin Wu, Guosheng Gu, Huajian Ren, Song Liu, Zhiwu Hong, Ranran Li, Yuan Li, Kun Guo, Xiuwen Wu, Jieshou Li
Article
Infectious Diseases
Guanwei Li, Jianan Ren, Qin Wu, Dong Hu, Gefei Wang, Xiuwen Wu, Song Liu, Yin Wu, Guosheng Gu, Jieshou Li
SURGICAL INFECTIONS
(2015)
Article
Gastroenterology & Hepatology
Guanwei Li, Jianan Ren, Gefei Wang, Qiongyuan Hu, Qin Wu, Xiuwen Wu, Ranran Li, Kun Guo, Yuan Li, Guosheng Gu, Huajian Ren, Zhiwu Hong, Jieshou Li
DIGESTIVE AND LIVER DISEASE
(2016)
Article
Nutrition & Dietetics
G. Li, J. Ren, G. Wang, D. Hu, G. Gu, S. Liu, H. Ren, X. Wu, J. Li
EUROPEAN JOURNAL OF CLINICAL NUTRITION
(2014)
Article
Immunology
Guanwei Li, Jianan Ren, Gefei Wang, Guosheng Gu, Dong Hu, Huajian Ren, Zhiwu Hong, Xiuwen Wu, Song Liu, Jieshou Li
INTERNATIONAL IMMUNOPHARMACOLOGY
(2014)
Article
Immunology
Guanwei Li, Huajian Ren, Xiuwen Wu, Qiongyuan Hu, Zhiwu Hong, Gefei Wang, Guosheng Gu, Jianan Ren, Jieshou Li
INTERNATIONAL IMMUNOPHARMACOLOGY
(2020)
Article
Pharmacology & Pharmacy
Paola Orlandi, Marta Banchi, Francesca Vaglini, Marco Carli, Stefano Aringhieri, Arianna Bandini, Carla Pardini, Cristina Viaggi, Michele Lai, Greta Ali, Alessandra Ottani, Eleonora Vandini, Patrizia Guidi, Margherita Bernardeschi, Veronica La Rocca, Giulio Francia, Gabriella Fontanini, Mauro Pistello, Giada Frenzilli, Daniela Giuliani, Marco Scarselli, Guido Bocci
Summary: This study investigates the role of MC4R in melanoma and the use of the selective antagonist ML in combination with vemurafenib. The results show that ML can inhibit melanoma cell proliferation and induce apoptosis through the inhibition of ERK1/2 phosphorylation and reduction of BCL-XL expression. The combination of vemurafenib and ML exhibits a synergistic effect in vitro and inhibits tumor growth in vivo without causing adverse effects.
BIOCHEMICAL PHARMACOLOGY
(2024)
Article
Pharmacology & Pharmacy
Conor J. Bloxham, Katina D. Hulme, Fabrizio Fierro, Christian Fercher, Cassandra L. Pegg, Shannon L. O'Brien, Simon R. Foster, Kirsty R. Short, Sebastian G. B. Furness, Melissa E. Reichelt, Masha Y. Niv, Walter G. Thomas
Summary: Bitter taste receptors (T2Rs) are a type of G protein-coupled receptors that allow humans to detect aversive and toxic substances. This study characterized the functional properties of previously identified T2Rs in human cardiac tissues and their naturally occurring polymorphisms. The results showed differences in signaling among different T2R variants, and revealed a potential association between the T2R50 Tyr203 variant and cardiovascular disease.
BIOCHEMICAL PHARMACOLOGY
(2024)
Article
Pharmacology & Pharmacy
Lu Chen, Huanying Shi, Wenxin Zhang, Yongjun Zhu, Haifei Chen, Zimei Wu, Huijie Qi, Jiafeng Liu, Mingkang Zhong, Xiaojin Shi, Tianxiao Wang, Qunyi Li
Summary: This study demonstrates that Carfilzomib exhibits potent anti-tumor activity against esophageal squamous cell carcinoma (ESCC) by triggering mitochondrial apoptosis and reprogramming cellular metabolism. It has been identified that activating transcription factor 3 (ATF3) plays a crucial role as a cellular target in ESCC cells treated with Carfilzomib. Overexpression of ATF3 effectively counteracts the effects of Carfilzomib on ESCC cell proliferation, apoptosis, and metabolic reprogramming. Furthermore, ATF3 mediates the anti-tumor activity of Carfilzomib, suggesting its potential as a therapeutic agent for ESCC.
BIOCHEMICAL PHARMACOLOGY
(2024)
Review
Pharmacology & Pharmacy
Xing Zhang, Xiang Li, Ran Xia, Hong-Sheng Zhang
Summary: This review summarizes recent progress on the mechanisms of ferroptosis resistance in cancer and highlights the role of redox status and metabolism. Combination therapy for ferroptosis has great potential in treating resistant malignant tumors.
BIOCHEMICAL PHARMACOLOGY
(2024)